麻豆传媒

Dr. Christina Li received her medical degree from the Columbia College of Physicians and Surgeons. She completed her residency in general surgery at the University of Maryland and was also a research fellow at the Maryland Center for Videoscopic Surgery. She completed a fellowship in minimally invasive and bariatric surgery at the University of Pennsylvania. She has been performing bariatric surgery for LifeBridge Health since 2004 and is a founding member of Sinai Hospital's Bariatric Center for Excellence.

Steven K. Libutti, MD, FACS, was appointed as Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. In addition to his leadership roles within Rutgers University, Dr. Libutti also serves as Senior Vice President of Oncology Services for RWJBarnabas Health, further strengthening the university鈥檚 partnership with the healthcare system. He is also a Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics at the Rutgers School of Arts and Sciences Department of Genetics.

Most recently, Dr. Libutti served as Director for the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is the immediate Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas.

The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and blood vessel formation in tumors. He is studying tumor neovascular formation and the interaction between tumor cells, endothelial cells and the components of the tumor microenvironment including fibroblasts and cancer stem cells. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L.

After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch.  He has published over 280 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds seven U.S. patents. 

Clinical Expertise:
Neuroendocrine tumors, thyroid cancer, parathyroid tumors, pancreatic cancer, liver cancer, gastrointestinal (GI) cancers, minimally invasive surgery, and clinical trials.

, is a gynecologic oncologist who specializes in the surgical management of female reproductive system cancers, including ovarian, uterine, cervical, vulvar and vaginal cancer. His expertise includes diagnostic and therapeutic procedures, including minimally invasive surgery, chemotherapy and novel drugs.
Eskander is also experienced in clinical trial development and aims to provide individuals with access to innovative medicines during their treatment. He is a member of  and the clinical trials office director for oncology.
As an assistant professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California San Diego, Eskander instructs medical students, residents and fellows. His research focuses on immunotherapy, targeted therapies for treating clear cell and endometrioid ovarian cancer, quality of life in cancer patients, and end-of-life care.
Eskander speaks Arabic and Spanish fluently.

Eric Strauch, MD has particiluar interests in pediatric surgical oncology, minimally invasive surgery, congenital anomalies, and hernias.  He will take care of any patient with any surgical problem both large and small.
Dr. Strauch completed his undergraduate degree at the Johns Hopkins University.  He received his medical degree from the University of Maryland School of Medicine as well as his gerneral surgery training at the University of Maryland.  He completed his traind in pediatric surger  at the Johns Hopkins/University of Maryland combined training program.  
Dr. Strauch has beend named a Top Doctor in the specialty of General Pediatric Surgery by Baltimore Magazine  from 2012-2022.
Medical School:



University of Maryland School of Medicine, 1988



Internship:



University of Maryland Medical Center, 1989



Residency:



University of Maryland Medical Center, 1994



Fellowship:



Johns Hopkins Hospital - PEDIATRIC SURGERY, 1996

Steven K. Libutti, MD, FACS was appointed Director of Rutgers Cancer Institute and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. On October 17th, 2024, Dr. Libutti was named the inaugural William N. Hait Director of Rutgers Cancer Institute. In addition to his leadership roles within Rutgers University, Dr. Libutti serves as Senior Vice President of Oncology Services for RWJBarnabas Health. He is also a Distinguished Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics, Rutgers School of Arts and Sciences. 
 
After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the National Cancer Institute (NCI) in surgical oncology. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch. Following his time at the NCI, he served as the Director of the Montefiore Einstein Center for Cancer Care and as an Associate Director of the Albert Einstein Cancer Center for eight years prior to joining Rutgers and RWJBarnabas Health.
 
Dr. Libutti is an internationally known expert in the management of neuroendocrine tumors and Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas. The recipient of funding from the NCI for the past 25 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment as well as on a better understanding of the tumor suppressor genes MEN1 and FILIP1L. He has published over 300 peer reviewed journal articles, is Editor-in-Chief Emeritus of the Springer-Nature Journal Cancer Gene Therapy and holds eleven U.S. patents. Dr. Libutti has successfully navigated Rutgers Cancer Institute’s P30 CCSG Comprehensive Cancer Center Award through two competitive renewals, the most recent of which in 2023 achieved the Center’s highest score to date placing it among the top centers in the US.